Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882634 | 1.00 | LMNA (0.51) | LMNAGAACTNNB1WNT3ANFKB1 | |
| SCHEMBL19863264 | 0.79 | LMNA (0.56) | LMNAGAACTNNB1WNT3ANFKB1 | |
| SCHEMBL17848764 | 0.78 | LMNA (0.55) | LMNAGAACTNNB1WNT3ANFKB1 | |
| SCHEMBL30096834 | 0.78 | LMNA (0.55) | LMNAGAACTNNB1WNT3ANFKB1 | |
| Water SCHEMBL3122500 | 0.78 | LMNA (0.55) | LMNAGAACTNNB1WNT3ANFKB1 | |
| SCHEMBL4888102 | 0.76 | CES2 (0.54) | LMNAGAAMAOB | |
| SCHEMBL4888097 | 0.76 | CES2 (0.54) | LMNAGAAMAOB | |
| SCHEMBL11783125 | 0.75 | LMNA (0.51) | LMNAGAACTNNB1WNT3ANFKB1 | |
| SCHEMBL28365387 | 0.75 | LMNA (0.51) | LMNAGAACTNNB1WNT3ANFKB1 | |
| SCHEMBL11783131 | 0.75 | LMNA (0.51) | LMNAGAACTNNB1WNT3ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227787-A1 | Use of New Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2008-09-18 | — | — | US | disclosed |
| EP-1725227-A1 | USE OF NEW LIPOXYGENASE INHIBITORS | Biolipox AB (SE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005084656-A1 | USE OF NEW LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227787-A1 | Use of New Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | LMNA 2096/4885GAA 2082/4885CTNNB1 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.